Eris Lifesciences fined ₹4.25L each by BSE, NSE for board composition

Eris Lifesciences Limited has been fined ₹4,24,800 each by BSE and NSE for non-compliance with Regulation 17(1) of SEBI Listing Regulations concerning the composition of its Board of Directors for the quarter ended March 31, 2026. The company clarified that the non-compliance arose from a board vacancy due to an Independent Director's term completion, which has since been filled on March 14, 2026. Eris Lifesciences states it is now compliant and remains committed to regulatory adherence. The financial impact is limited to the penalty amount.